Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels

Wiener Klinische Wochenschrift

Volumn 119, Issue 21-22, 2007, Pages 626-632

  Jarai, Rudolf ^a   Iordanova, Nelly ^a   Jarai, Robert ^b   Jarai, Ferenc ^a   Raffetseder, Annamaria ^c   Woloszczuk, Wolfgang ^c   Gyöngyösi, Mariann ^a   Geyer, Georg ^c   Wojta, Johann ^d   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF PÉCS   (Hungary)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Natriuretic peptides; TIMI risk score; Unstable coronary artery disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DISEASE CLASSIFICATION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RISK ASSESSMENT; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; AUSTRIA; BIOLOGICAL MARKERS; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 36949029366     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0892-2     Document Type: Article

References (23)

1. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 (2): 131-138
2. Richards AM, Doughty R, Nicholls MG, Macmahon S, Ikram H, Sharpe N, et al (1999) Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99 (6): 786-792
3. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (14): 1014-1021
4. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (23): 2913-2918
5. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108 (3): 275-281
6. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (20): 3206-3212
7. Jarai R, Wojta J, Huber K (2005) Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerations. Thromb Haemost 94 (5): 926-932
8. Antman EM, Cohen M, Bernink PJLM, McCabe MCH, Horacek T, Papuchis G, et al (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284: 835-842
9. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E (2002) An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. European Heart Journal 23 (3): 223-229
10. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (8): 1264-1272
11. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al (2001) Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction. JAMA 286 (19): 2405-2412
12. Jordanova N, Gyongyosi M, Aliasghar K, Falkensammer C, Zorn G, Wojta J, et al (2005) New cut-off values of cardiac markers for risk stratification of angina pectoris. Int J Cardiol 99: 429-435
13. Fonarow G, Adams KF, Jr., Abraham WT, Yancy CW, Boscardin WJ, for the ADHERE Scientific Advisory Committee SG, and Investigators (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure. Jama 293 (5): 572-580
14. Selker HP, Griffith JL, Patil S, Long WJ, D'Agostino RB (1995) A comparison of performance of mathematical pre dictive methods for medical diagnosis: identifying acute cardiac ischemia among emergency department patients. J Investig Med 43 (5): 468-476
15. Hanley J, McNeil B (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (3): 839-843
16. Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J (2004) Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 25 (10): 859-866
17. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T (2000) Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 23 (10): 776-780
18. Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT (2000) Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol 23 (4): 285-288
19. Marumoto K, Hamada M, Aburaya M, Hiwada K (1995) Augmented secretion of atrial and brain natriuretic peptides during dynamic exercise in patients with old myocardial infarction. Jpn Circ J 59 (11): 715-724
20. Morrow DA, Braunwald E (2003) Future of biomarkars in acute coronary syndromes - moving toward a multimarker strategy. Circulation 108: 250-252
21. Jernberg T, Stridsberg M, Venge P, Lindahl B (2002) N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40: 437-445
22. Jernberg T, Lagerqvist B, Stridsberg M, Venge P, Wallentin L, Lindahl B (2002) N-terminal pro brain natriuretic peptide identifies patients with unstable coronary diseases who benefit from an early invasive strategy. Circulation 106: 2439
23. Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2003) Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 49 (6 Pt 1): 976-979